NLRP3 and metabolic dysfunction-associated steatotic liver disease: (Huang et al., 2021) MCC950 (a NLRP3 selective inhibitor) attenuated IL-1β production through inflammasome suppression, which improved NAFLD pathology and fibrosis in obese diabetic mice.